Molecular Profiling of Laser-Microdissected Matched Tumor and Normal Breast Tissue Identifies Karyopherin α2 as a Potential Novel Prognostic Marker in Breast Cancer

Purpose: The aim of the present study was to identify human genes that might prove useful in the diagnosis and therapy of primary breast cancer. Experimental Design: Twenty-four matched pairs of invasive ductal breast cancer and corresponding benign breast tissue were investigated by a combination of laser microdissection and gene expression profiling. Differential expression of candidate genes was validated by dot blot analysis of cDNA in 50 pairs of matching benign and malignant breast tissue. Cellular expression of candidate genes was further validated by RNA in situ hybridization, quantitative reverse transcription-PCR, and immunohistochemistry using tissue microarray analysis of 272 nonselected breast cancers. Multivariate analysis of factors on overall survival and recurrence-free survival was done. Results: Fifty-four genes were found to be up-regulated and 78 genes were found to be down-regulated. Dot blot analysis reduced the number of up-regulated genes to 15 candidate genes that showed at least a 2-fold overexpression in >15 of 50 (30%) tumor/normal pairs. We selected phosphatidic acid phosphatase type 2 domain containing 1A (PPAPDC1A) and karyopherin α2 (KPNA2) for further validation. PPAPDC1A and KPNA2 RNA was up-regulated (fold change >2) in 84% and 32% of analyzed tumor/normal pairs, respectively. Nuclear protein expression of KPNA2 was significantly associated with shorter overall survival and recurrence-free survival. Testing various multivariate Cox regression models, KPNA2 expression remained a highly significant, independent and adverse risk factor for overall survival. Conclusions: Gene expression profiling of laser-microdissected breast cancer tissue revealed novel genes that may represent potential molecular targets for breast cancer therapy and prediction of outcome.

[1]  Andrea Bild,et al.  Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy , 2006, Clinical Cancer Research.

[2]  G. Blobel,et al.  Karyopherins and nuclear import. , 2001, Current opinion in structural biology.

[3]  M. Hodel,et al.  Dissection of the karyopherin alpha nuclear localization signal (NLS)-binding groove: functional requirements for NLS binding. , 2003, The Journal of biological chemistry.

[4]  C. Pilarsky,et al.  Gene expression profiles of microdissected pancreatic ductal adenocarcinoma , 2003, Virchows Archiv.

[5]  A. Hartmann,et al.  The molecular epidemiology of p53 gene mutations in human breast cancer. , 1997, Trends in genetics : TIG.

[6]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[7]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Morris,et al.  Roles for lipid phosphate phosphatases in regulation of cellular signaling. , 2002, Biochimica et biophysica acta.

[9]  David I. Smith,et al.  HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma , 2004, Oncogene.

[10]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[11]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[12]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Loening,et al.  ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions , 2003, The Prostate.

[14]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[15]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[16]  C. Graziano.  HER-2 breast assay, linked to Herceptin, wins FDA's okay. , 1998, CAP today.

[17]  Christian Pilarsky,et al.  Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival , 2005, The Journal of pathology.

[18]  M. Kai,et al.  Phosphatidic acid phosphatase from mammalian tissues: discovery of channel-like proteins with unexpected functions. , 1997, Biochimica et biophysica acta.

[19]  S. Ethier.  Identifying and Validating Causal Genetic Alterations in Human Breast Cancer , 2003, Breast Cancer Research and Treatment.

[20]  E. Devilard,et al.  Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. , 2002, Human molecular genetics.

[21]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[22]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[23]  Armin A. Weiser,et al.  Expression levels of the putative zinc transporter LIV‐1 are associated with a better outcome of breast cancer patients , 2005, International journal of cancer.

[24]  J. Xu,et al.  Structural organization of mammalian lipid phosphate phosphatases: implications for signal transduction. , 1999, Biochimica et biophysica acta.

[25]  Rainer M. Bohle,et al.  Real-time quantitative RT–PCR after laser-assisted cell picking , 1998, Nature Medicine.

[26]  F. Couch,et al.  Localization of BRCA1 and a splice variant identifies the nuclear localization signal , 1997, Molecular and cellular biology.

[27]  R. Knuechel,et al.  Laser Microdissection and Microsatellite Analyses of Breast Cancer Reveal a High Degree of Tumor Heterogeneity , 2001, Pathobiology (Basel).

[28]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[29]  T. Teratani,et al.  S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. , 2004, European journal of cancer.

[30]  F. Couch,et al.  Localization of BRCA 1 and a Splice Variant Identifies the Nuclear Localization Signal , 1996 .

[31]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[32]  R. Peña,et al.  Localization of importin α (Rch1) at the plasma membrane and subcellular redistribution during lymphocyte activation , 2003, Chromosoma.

[33]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[34]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[35]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[36]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[37]  J. Welsh,et al.  Molecular classification of human carcinomas by use of gene expression signatures. , 2001, Cancer research.

[38]  R. Vossen,et al.  Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.

[39]  C. Pilarsky,et al.  Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues. , 1999, Nucleic acids research.

[40]  C. Emerson,et al.  Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. , 2001, Science.

[41]  A. Balmain,et al.  Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. , 2005, Carcinogenesis.